Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary)
- Indications Kidney-pancreas transplant rejection; Pancreas transplant rejection; Renal transplant rejection
- Focus Therapeutic Use
- 29 Mar 2018 Status changed from active, no longer recruiting to completed.
- 29 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 29 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.